Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZL-3101 · 1 trial · 1 indication
To evaluate efficacy of Fugan ointment applied to involved skin of subjects with mild to moderate subacute eczema
| Arm | Type | Description |
|---|---|---|
| ZL-3101(Fugan) bid group | EXPERIMENTAL | Fugan AM + Fugan PM |
| ZL-3101(Fugan) qd group | EXPERIMENTAL | Fugan AM + Placebo PM |
| placebo group | PLACEBO_COMPARATOR | Placebo AM + Placebo PM |
| Name | Type | Description |
|---|---|---|
| ZL-3101 | DRUG | A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical |
| Placebo | DRUG | A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical |
Inclusion Criteria: 1. Male or female subjects between 18 and 65 years of age inclusive, at the time of signing the informed consent; from outpatient clinic; 2. Subjects with a diagnosis of subacute eczema (Zhao 2001). Subacute eczema is often developed from improperly treated acute eczema or a few...
ZL-3101 is an investigational small molecule being developed for the treatment of eczema, also known as subacute eczema. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied for its efficacy and safety in patients with this skin condition.
ZL-3101 is being developed by Zai Lab Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ZLAB. The company is conducting clinical research on this investigational small molecule for the treatment of eczema.
ZL-3101 is in Phase 2 clinical development. A Phase 2 clinical trial evaluating the drug in patients with subacute eczema has been completed. The drug is investigational and has not received regulatory approval for any use.
ZL-3101 has one completed Phase 2 clinical trial, identified as NCT03134352, titled "Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema." This randomized, double-blind, placebo-controlled trial enrolled 290 participants in China.
No, ZL-3101 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of eczema. The drug has not completed the clinical trial process required for regulatory approval and remains under investigation.